d(GC) - Association of Biotechnology and Pharmacy

Current Trends in Biotechnology and Pharmacy
Vol. 6 (2) 166-172 April 2012, ISSN 0973-8916 (Print), 2230-7303 (Online)
the invitro systems. Antitrypsin provided
significant improvement in stability when
compared to other inhibitors of ecto-peptidases.
The lipoprotein based drug delivery approach
offered better tumor barrier penetration due to
the proposed endocytotic uptake and also helped
in maintaining the immunogenic potential of the
peptide. Thus, the in vitro results indicate that
these delivery approaches have potential in
improving in vivo efficacy of PADRE.
References
1. Ruddy, K. (2008). Immunotherapy for breast
cancer. The Breast Cancer Report, 1 (1).
2. Piura, E. and Piura, B. (2011). Autoantibodies
to Tailor-Made Panels of Tumor-
Associated Antigens in Breast Carcinoma.
Journal of Oncology, 2011. Article ID 982425.
3. Parmiani, G., Castelli, C., Dalebra, P.,
Mortarini, R., Rivoltini L., Marincola F. and
Anichini, A. (2002). Cancer Immunotherapy
With Peptide-Based Vaccines: What Have
We Achieved? Where Are We Going?
Journal of the National Cancer Institute, 94
(11): 805-818.
4. Wenning, L. and Murphy, R. (1999). Coupled
cellular trafficking and diffusional limitations
in delivery of immunotoxins to multicell tumor
spheroids. Biotechnology and
5.
Bioengineering, 62: 562-75.
Poondru, S., Marasanapalle, V., Saraf, P. and
Jasti, B. (2012). Development and Validation
of Reversed Phase HPLC Method for
Analysis of Immunotherapeutic Peptide
PADRE and its Applications. Current Trends
in Biotechnology and Pharmacy, 6 (1):35-43.
6. Takaori, K., Burton, J. and Donowitz, M.
(1986). The transport of an intact
oligopeptide across adult mammalian
jejunum. Biochemical and Biophysical
Research Communications, 137: 682-687.
7. Ziv, E., Lior, O., Kidron, M. (1987). Absorption
of protein via the intestinal wall. A quantitative
model. Biochemical Pharmacology, 36:
1035-1039.
Delivery Strategies to improve PADRE
172
8. Dubowchik, G.M. and Walker, M.A. (1999).
Receptor-mediated and enzyme-dependent
targeting of cytotoxic anticancer drugs.
Pharmacology and Therapeutics, 83: 67-123.
9. Masquelier, M., Vitols, S., Pålsson M., Mårs,
U., Larsson, B.S. and Peterson, C.O. (2000).
Low density lipoprotein as a carrier of
cytostatics in cancer chemotherapy: study of
stability of drug-carrier complexes in blood.
Journal of Drug Targeting, 8(3): 155-164.
10. Pierotti, A., Dong, K.W., Glucksman, M.J.,
Orlowski, M. and Roberts, J.L. (1990).
Molecular cloning and primary structure of
rat testes metalloendopeptidase EC
3.4.24.15. Biochemistry, 29(45): 10323-9,
Erratum in Biochemistry, (1994). Jan 18;
33(2):622.
11. Barrett, C.H., Dodgson, K.S. and White, G.F.
(1980). Further studies on the substrate
specificity and inhibition of the stereospecific
CS2 secondary alkylsulpho-hydrolase of
Comamonas terrigena. Biochemical Journal,
191: 467-473.
12. Danforth, E.and Moore, R.O. (1959)
Intestinal absorption of insulin in the rat.
Endocrinology, 65:118-123.
13. Bijsterbosch, M.K. and van Berkel, J.C.
(1990). Native and modified lipoproteins as
drug delivery system. Advanced Drug
Delivery Reviews, 5(3): 231–251.
14. Masquelier, M., Tirzitis, G., Peterson C.O.,
Pålsson, M., Amolins, A., Plotniece, M.,
Plotniece, A., Makarova, N. and Vitols, S.G.
(2000). Plasma stability and cytotoxicity of
lipophilic daunorubicin derivatives
incorporated into low density lipoproteins.
European Journal of Medicinal Chemistry,
35: 429"438.
15. Honglin J., Lovell, J., Chen, J., Lin, Q., Ding,
L., Ng, K., Pandey, R.K., Manoharan, M.,
Zhang, Z. and Zheng G. (2012). Mechanistic
Insights into LDL Nanoparticle-Mediated
siRNA Delivery. Bioconjugate chemistry,
23(1): 33-41.